Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) Tax Provisions (2021 - 2024)

Prime Medicine filings provide 4 years of Tax Provisions readings, the most recent being -$134000.0 for Q2 2024.

  • On a quarterly basis, Tax Provisions fell 532.26% to -$134000.0 in Q2 2024 year-over-year; TTM through Mar 2025 was -$134000.0, a 335.09% decrease, with the full-year FY2023 number at -$279000.0, up 70.57% from a year prior.
  • Tax Provisions hit -$134000.0 in Q2 2024 for Prime Medicine, down from $134000.0 in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $1.4 million in Q4 2021 to a low of -$2.4 million in Q3 2021.
  • Median Tax Provisions over the past 4 years was -$134000.0 (2024), compared with a mean of -$201454.5.
  • The widest YoY moves for Tax Provisions: up 166.34% in 2024, down 532.26% in 2024.
  • Prime Medicine's Tax Provisions stood at $1.4 million in 2021, then plummeted by 113.47% to -$186000.0 in 2022, then soared by 41.94% to -$108000.0 in 2023, then dropped by 24.07% to -$134000.0 in 2024.
  • The last three reported values for Tax Provisions were -$134000.0 (Q2 2024), $134000.0 (Q1 2024), and -$108000.0 (Q3 2023) per Business Quant data.